For example, patients with NSCLC harboring EGFR L858R or atypical activating mutations have shorter progression-free survival with osimertinib compared to patients whose tumors have the classic EGFR ∆E746-A750 exon 19 deletion12,14. This evidence concerns the gene EGFR and non-small cell lung carcinoma.